PepGen Study result
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to the PepGen conference call to discuss positive top-line results from the 10 mg/kg MAD cohort in the phase II FREEDOM2 DM1 study. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's questions, we would ask that each person limit themselves to one question and one follow-up. As a reminder, this call is being recorded today. I would now like to turn the conference call over to Laurence Watts of New Street Investor Relations.
Please go ahead. Thank you, operator.
Joining us on the call today are PepGen's President and Chief Executive Officer, James McArthur, Chief Financial Officer, Noel Donnelly, Executive Vice President, Head of Research and Development, Dr. Paul Streck, and Dr. Johanna Hamel, Associate Professor of Neurology, Pathology, and Laboratory Medicine at the University of Rochester. In addition to this data, PepGen today released third quarter 2026 financial results and corporate highlights. Both press releases and this presentation are available on our investors page at pepgen.com. During this call, management will make forward-looking statements, including statements related to its phase II trial of PGN-EDODM1, as well as the timing of additional or future data from the studies and PepGen's development plans. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties.
Factors that could cause these results to be different from these statements include factors PepGen describes in its security filings, including its annual report on Form 10-K and quarterly reports on Form 10-Q. PepGen undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations. With that, I will turn the call over to James McArthur, President and Chief Executive Officer of PepGen.
James? Thank you, Laurence. Good morning, everyone.
Thank you for joining us for today's call. As Laurence mentioned, we're joined today by Dr. Paul Streck, PepGen's Head of R&D, and Dr. Johanna Hamel of the University of Rochester, one of the principal investigators in our FREEDOM study. I'll provide a high-level summary of the data, followed by Dr. Streck, who will review the technology behind EDODM1 and review the trial design, the safety and splicing results. Dr. Hamel will follow and review the clinical functional endpoints and what these results could potentially mean for people living with DM1. Finally, we'll conclude with Q&A. We're very pleased to report the results from the 10 mg/kg PGN-EDODM1 FREEDOM2 clinical trial today. Along with the excellent splicing correction, we also observed improvement in multiple key functional measures, assessing myotonia, hand grip strength, mobility and balance, and ambulation.
In addition, PGN-EDODM1 continues to demonstrate a favorable safety profile. In short, these positive data strengthen our belief that PGN-EDODM1 has the potential, if approved, to set a new standard for the treatment of DM1. Four doses of PGN-EDODM1 at 10 mg/kg resulted in a 46.5% mean improvement in splicing correction, with four of six participants having more than 50% splicing correction. Based on publicly reported clinical data, this is the highest splicing correction reported to date in a multiple-dose DM1 study. Turning to functional measures, we observed a 4.3-second improvement in myotonia, as measured by video hand opening time at week 13, which was associated with splicing correction of CLCN1, a muscle chloride channel driving myotonia in DM1. We saw further functional benefit across both proximal and distal muscle groups impacted by DM1 in a dose-dependent manner.
At 10 mg/kg, we observed notable improvements in hand grip strength, timed up and go, and 10-meter walk/run test, providing compelling evidence of PGN-EDODM1's potential to address multiple clinical manifestations of DM1. With respect to safety, PGN-EDODM1 at 10 mg/kg continues to present a favorable tolerability and safety profile, with no serious adverse events, adverse events of special interest, dose-limiting toxicities, or discontinuations. Importantly, we did not observe any cumulative increase in safety signals with multiple doses, and four adverse events related to kidney biomarkers were all mild. In summary, these positive data strengthen our belief that PGN-EDODM1 has the potential, if approved, to set a new standard for the treatment of DM1. I'll now hand over the presentation to my colleague, Dr. Paul Streck, Head of R&D, to take you through our clinical results in more detail.
Thank you, James. Myotonic dystrophy type 1, or DM1, is a devastating rare genetic disease which increases in severity in each successive generation. It robs patients of critical function and ultimately shortens their lives. It affects 110,000 or more patients in the U.S. and E.U., and there are no approved therapies that address the underlying pathology of the disease. To remind everyone, DM1 is caused by expanded CTG repeats in the dystrophia myotonica protein kinase, or DMPK, gene. This results in toxic DMPK RNA that disrupts normal RNA splicing and drives the disease. PGN-EDODM1 is designed specifically to bind to the CUG repeat in the pathogenic DMPK RNA with the goal of restoring splicing. A key aspect of its design is the use of our enhanced delivery oligonucleotide, or EDO platform.
Our EDO technology uses an engineered peptide for receptor-independent oligonucleotide delivery and is designed to support broad tissue delivery, which is believed to be critically important given the multisystemic nature of this condition. Once inside the cell, our EDO technology promotes endosomal escape and delivery of the therapeutic oligonucleotide into the nucleus. In DM1 cells in vitro, PGN-EDODM1 demonstrates up to a 98-fold increase in nuclear uptake compared with naked oligonucleotide. Nuclear delivery is critical because the pathogenic DMPK RNA that drives the underlying disease of DM1 resides in the nucleus. Unlike many other approaches in the clinic that indiscriminately degrade normal and pathogenic DMPK RNA, the PGN-EDODM1 oligonucleotide is designed to bind selectively to the expanded CUG repeats in the pathogenic DMPK transcript. This is designed to disrupt the stem-loop structure of this pathogenic RNA without degrading normal DMPK RNA.
By disrupting these structures of the pathogenic DMPK RNA, trapped MBNL1 protein is released, allowing it to resume its normal role in RNA splicing. This combination of broad tissue delivery and correction of mis-splicing is the core rationale for PGN-EDODM1. The results we are presenting today provide important clinical evidence of how that rationale is translating into potential impact for individuals living with DM1. Here you see the design of FREEDOM2, our phase II multiple ascending dose study. The study includes three dose cohorts. Each cohort enrolls eight participants randomized three to one to receive PGN-EDODM1 or placebo. Participants receive four doses administered every four weeks over a 12-week period. Today, we will take you through the results from the 10 mg/kg dose cohort. Here are the baseline characteristics of the study.
As you can see, participants were fairly well-balanced, most important in terms of baseline splicing index and CTG repeat number. Our findings to date continue to support a favorable safety profile. PGN-EDODM1 was generally well tolerated across the five and 10 mg/kg cohorts. All participants completed all doses, and all adverse events were mild or moderate in severity. Importantly, there were no serious or severe adverse events, adverse events of special interest, dose-limiting toxicities, or discontinuation. We will discuss kidney function biomarkers on the next slide, but we saw no notable changes in liver or hematologic values and no cardiovascular events. We also saw no anti-drug antibodies. Here's a closer look at certain renal biomarkers and related laboratory measures collected during the study. There were four renal treatment-emergent adverse events, all of which were mild.
At 10 mg/kg, we observed a transient increase in urine albumin-to-creatinine ratio, or UACR, following the first dose. Mean UACR returned toward baseline, and the magnitude of the increase diminished with subsequent dosing. There were no meaningful changes in the eGFR. Mean serum creatinine levels remained within normal range. We observed one participant with a single creatinine value with above-normal measurement. It resolved in 24 hours and is considered clinically insignificant by a consulting nephrologist. Separately, a different participant at 10 mg/kg had one magnesium reading below normal. No intervention occurred. Overall, these findings support the favorable renal safety profile to date. Now turning to biological activity. We are extremely encouraged by the magnitude of splicing correction observed at 10 mg/kg. As you can see from the right-hand panel, following four doses, PGN-EDODM1 produced a 46.5% mean improvement in splicing.
This was measured using the industry standard 22-transcript panel. Let me reiterate again, based on reported clinical data, this is the highest mean splicing correction reported to date in a multiple-dose DM1 study, and we believe it provides evidence of target engagement. It also builds on the dose response observed in FREEDOM, our single ascending dose study. With repeat dosing in FREEDOM2, we have seen a significant step up in splicing correction between five and 10 mg/kg. We believe the magnitude of this effect is especially compelling. On the next slide, you can see that it was supported by a meaningful level of consistency across participants. Four of the six participants at 10 mg/kg achieved splicing improvement greater than 50%, with individual improvements ranging up to 77%.
This has been particularly notable in the context of natural history data showing that approximately 11% of individuals in a DM1 natural history study demonstrated greater than 20% splicing improvement over a two to three-month period, as opposed to the 83% of individuals in the 10 mg/kg arm of FREEDOM2. This reinforces that the compelling improvement in mean splicing was not driven by a few participants, further strengthening the evidence of robust target engagement with PGN-EDODM1. Turning to muscle exposure. Following four doses of PGN-EDODM1, we observed increasing concentration in tibialis anterior muscle. In FREEDOM2, mean tissue concentration reached 150 nanograms per gram at five mg/kg, and increased to 222 nanograms per gram at 10 mg/kg, measured seven days after the fourth dose. The single dose results from FREEDOM are included for context and were measured 28 days after dosing.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
13 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
